<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01398189</url>
  </required_header>
  <id_info>
    <org_study_id>SNUBH 04-2011-050</org_study_id>
    <nct_id>NCT01398189</nct_id>
  </id_info>
  <brief_title>F-18 Altanserin PET Study of Patients Receiving Clozapine</brief_title>
  <acronym>APC</acronym>
  <official_title>Validation of Molecular Imaging Technologies for Early Clinical Trials</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Bundang Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Bundang Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To examine the feasibility of molecular imaging markers in clinical psychopharmacology
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Clinical evaluation of patients with psychiatric disorders is mainly dependent on patients'
      reports and clinicians' observations. In order to develop objective and quantifiable measures
      of psychopathology, molecular imaging techniques will be used in patients receiving
      clozapine.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2011</start_date>
  <completion_date type="Anticipated">July 2015</completion_date>
  <primary_completion_date type="Anticipated">July 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>pharmacodynamics of F-18 artanserin</measure>
    <time_frame>84 days</time_frame>
    <description>PET imaging with F-18 altanserin infusion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>serum level of clozapine and metabolites</measure>
    <time_frame>84 days</time_frame>
    <description>dose-response relationship between clozapine and receptor occupancy</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Schizophrenia</condition>
  <condition>Schizoaffective Disorder</condition>
  <arm_group>
    <arm_group_label>clozapine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients with refractory schizophrenia or schizoaffective disorder</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>clozapine</intervention_name>
    <description>C-11 clozapine</description>
    <arm_group_label>clozapine</arm_group_label>
    <other_name>clozaril</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Overtly healthy males as determined by medical history and physical examination

          -  Age from 19 to 45 years

          -  Weight ≥ 45 kg and within ± 20% of IBW

          -  Clinical laboratory test results within normal reference range for the National Cancer
             Center, Hospital or results with minor deviations which are judged to be not
             clinically significant by the investigator

          -  Normal blood pressure and heart rate (supine and standing) as determined by the
             investigator

          -  Are reliable and willing to make themselves available for the duration of the study,
             and who will abide by the study restrictions

          -  Have given written informed consent

        Exclusion Criteria:

          -  Evidence of significant active hematologic disease

          -  History or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal,
             neurological disorders capable of altering the absorption, metabolism or elimination
             of drugs, or of constituting a risk factor when taking the study medication

          -  An episode of febrile disease or infectious disease within the past 2 weeks

          -  Evidence of significant active neuropsychiatric disease

          -  Regular use of drugs or abuse

          -  History of drug hypersensitivity or clinically significant allergic reactions of any
             origin

          -  Participation in a study involving administration of an investigational compound
             within the past 30 days

          -  Use of any current medication

          -  Smoking history for recent 3 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jae Seung Chang, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Seoul National University Bundang Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jae Seung Chang, MD, PhD</last_name>
    <phone>82 31 787 7437</phone>
    <email>cjs0107@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Se Young Lee, MD</last_name>
    <phone>82 31 787 7439</phone>
    <email>zoayo2000@hanmail.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam</city>
        <state>Gyeonggi</state>
        <zip>463-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Se Young Lee, MD</last_name>
      <phone>82 31 787 7439</phone>
      <email>zoayo2000@hanmail.net</email>
    </contact>
    <investigator>
      <last_name>Kyooseob Ha, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 19, 2011</study_first_submitted>
  <study_first_submitted_qc>July 19, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 20, 2011</study_first_posted>
  <last_update_submitted>November 19, 2013</last_update_submitted>
  <last_update_submitted_qc>November 19, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 21, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Bundang Hospital</investigator_affiliation>
    <investigator_full_name>Jae Seung Chang</investigator_full_name>
    <investigator_title>Clinical Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>clozapine</keyword>
  <keyword>PET</keyword>
  <keyword>schizophrenia</keyword>
  <keyword>schizoaffective disorder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clozapine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

